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ALK-positive, advanced NSCLC in Argentina. Methods: A budget impact model 
we developed to evaluate two separate scenarios from a payer’s perspective. The 
model compared scenarios with and without crizotinib. In the crizotinib scenario all 
patients testing positive for the ALK mutation were given crizotinib. Comparators 
were platin-containing regimens (ex pemetrexed), platin/pemetrexed, erlotinib/gefi-
tinib, and crizotinib. Epidemiology, market basket, adverse event costs, and drug 
costs were informed through ten local physician questionnaires and published 
literature. The survey was administered to oncologists in six different private and 
public hospitals of varying sizes and locations in Argentina. Costs are in 2013 USD 
(1 USD = 5.88 ARS). Results: Considering the population of Argentina (42,610,981) 
and applying age based incidence rates, the number of lung cancer patients was 
estimated to be 12,139. Of those patients 82.5% were estimated to be have metastatic 
NSCLC and 74% were likely to be treated, leaving 7,411 treated patients in the model. 
The estimated one-year cost for treating these patients without crizotinib was esti-
mated to be $205,874,409. In the scenario including crizotinib, 154 patients (market 
uptake of 2.08%) were taken from other regimens and given crizotinib resulting in an 
estimated one-year cost of $224,651,145. The incremental total cost between these 
scenarios was $18,776,736 while the incremental costs per ALK+ patient and per 
member were $211 and $.04 respectively. These results were robust under standard 
parameter estimate variations. ConClusions: Adding crizotinib as a treatment 
option may have an acceptable budget impact under standard practices.
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objeCtives: In Brazil, health insurance companies (HIC) must, according to the law, 
offer coverage for intravenous (IVChem) antineoplastic drugs. The obligation to pay 
for oral drugs (OChem) was effective only after January 2014. Our goal was to evaluate 
the incremental costs and budgetary impact of the incorporation of OChem, using 
real world data, from the private payers’ perspective. Methods: During one year (Jun 
2012-mai 2013) we prospectively collected data on chemotherapy usage in 25 HIC, with 
a population of 3 million people from different regions in Brazil. First we calculated 
the costs of IVChem actually used. After that, we identified which patients would have 
formal indication for OChem either as a substitutive treatment or in association with 
IVChem. Then, we calculated the costs associated with this intervention. Later, the 
budgetary impact of using OChem for the eligible patients was calculated. Only drug 
acquisition costs were taken into account. We analyzed two scenarios: one with a 
total substitution of IVChem for OChem, when OChen treatment was less expensive 
than IVChem and another, using a “worst case scenario” approach, were OChem 
was used only in cases where it added costs. Results: During the one-year period, 
2,104 patients that received intravenous chemotherapy also had formal indication to 
receive OChem. If OChem had been used, in a rational protocol-based manner, there 
would have been an economy of R$ 0,10 (US$ 0,42) per HIC user per month. In the 
worst-case scenario, the incremental cost would be an additional R$ 0,39 (US$ 0,16) 
per HIC user per month. ConClusions: The budgetary impact secondary to OChem 
adoption may vary from decreasing costs to increasing them; depending on how they 
are used and to which patient they are prescribed. HIC should pay close attention to 
the profile of use of OChem in order to avoid unnecessary costs.
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objeCtives: In a Phase III clinical trial (Von Hoff, NEJM 2013) albumin-bound 
paclitaxel (nab-P) plus gemcitabine (nab-P/G) significantly improved median over-
all survival (OS) in first-line metastatic pancreatic cancer (1LmPanc) patients vs. 
gemcitabine (G) alone (8.7 vs. 6.6 months, hazard ratio 0.72, P< 0.001). The objective 
of this analysis is to estimate the budget impact of adding nab-P/G for 1LmPanc 
treatment at a US health plan. Methods: A budget impact model was built to 
estimate 1LmPanc costs for nab-P/G, G, Erlotinib + Gemcitabine (EG), Other G com-
binations (OG), and FOLFIRINOX (F), from a US health plan perspective in 2013 US 
dollars. Inputs for drug, administration, G-CSF, and adverse events were derived 
from prescribing information, publications, Medicare reimbursement rates, and 
other public sources. Sensitivity analysis assessed utilization mixes and elderly 
populations. Results: A 1,000,000-member health plan mirroring the US popula-
tion age mix would have 70 patients with 1LmPanc annually. The model assumed 
equal proportions of G, EG, OG, and F (25% of patients each) at baseline, and equal 
use (20% each) after nab-P/G 1LmPanc approval. Total course of therapy costs were 
G $2,634, EG $22,555, OG $10,840, F $39,437. Baseline total mPanc costs were $1.3 
million, or $0.11 per member per month (PMPM). Adding nab-P/G at $29,096 per 
course of therapy added $142,610, or $0.01 PMPM, to the baseline. In a sensitivity 
analysis with 50% of patients using nab-P/G, incremental cost was $0.03 PMPM. For 
a health plan population age 65-79, baseline cost of $0.48 PMPM rose $0.05 PMPM 
from nab-P/G. If only 70% of 1LmPanc patients received drug therapy, costs from nab-
P/G rose $0.01 from $0.08 PMPM at baseline. ConClusions: The budget impact of 
adding albumin-bound paclitaxel plus gemcitabine for a US health plan’s first-line 
metastatic pancreatic cancer patients was estimated at $0.01 PMPM; the impact 
was consistent across several sensitivity analyses.
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from peer reviewed literature. A multivariate sensitivity analysis using a Monte Carlo 
simulation was completed to ensure scientific rigour. Results: VATS lobectomies 
are associated with higher procedural costs, but this is offset by a shorter length of 
stay and a lower postoperative complication rate. The model establishes that for a 
Canadian hospital performing 150 lobectomies increasing the proportion of VATS 
cases from 25% to 75% allows for a potential cost savings of CAD $226,066.01 annu-
ally. ConClusions: In a Canadian hospital, VATS lobectomy is a more cost-effective 
procedure than open lobectomy for early stage lung cancer.
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objeCtives: Radium-223, an intravenously injected radioactive agent, is a new 
therapeutic option for CRPC patients with symptomatic bone metastases and no 
known visceral metastatic disease. This budget impact model (BIM) was developed 
from a United States (US) payer perspective to estimate the economic impact of 
adding radium-223 to current treatment options in this population. Methods: An 
Excel-based BIM evaluated costs of treating CRPC with symptomatic bone metas-
tases and no known visceral metastatic disease with available treatment options 
(chemotherapies, radionuclides, and oral antiandrogens) in a health plan with and 
without radium-223. One-year incremental costs were estimated for a hypothetical 
health plan with 1 million members. The prevalence of metastatic CRPC (mCRPC) 
patients was obtained from the national registry and published literature. Cost of 
therapy was obtained from Medicare average sales prices (ASP). Assumptions of out-
patient administration and laboratory utilization were derived from product-specific 
package inserts with costs transformed into costs per 4 weeks based on indicated 
dosing. Associated costs were derived from the Centers for Medicare & Medicaid 
Services (CMS) Physician Fee Schedule. Results: An estimated 220 patients were 
eligible for treatment with radium-223. Radium-223 was assumed to adopt 6.4% of 
the market in year 1 with equiproportional pull from available treatment options; 
a cost of $11,500 per 28-day cycle was assumed. In this base-case scenario, costs 
rose 1.7% ($208,755) or $0.02 per member per month (PMPM) compared to a health 
plan without radium-223. Sensitivity analyses, varying default inputs ± 10%, showed 
that results were robust, with greatest sensitivity to the number of radium-223 
doses ($0.01–$0.03 PMPM). Other key variables such as cycles of treatment, num-
ber of patients treated, and market share resulted in no change to PMPM budget 
impact. ConClusions: Economic modeling indicates that adding radium-223 to a 
health plan’s formulary minimally increases the PMPM cost by $0.02.
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objeCtives: Life Technologies has developed a 14-gene molecular assay (PervenioTM 
Lung RS) that provides mortality risk stratification in resected early-stage non-
squamous NSCLC. The test classifies patients as low, intermediate, or high-risk 
(for death), informing decisions about adjuvant chemotherapy use. Accordingly, 
high-risk patients may benefit from chemotherapy, and low-risk patients can avoid 
chemotherapy-associated morbidity and costs. Our objective was to estimate the 
budget impact of covering the assay in hypothetical commercial and Medicare 
health plans. Methods: We developed a Markov model to estimate costs before 
and after coverage of the 14-gene RS in commercial (age < 65) and Medicare (age 
65+) health plans with 1 million enrollees. Health plan age distributions and disease 
incidence were derived from the U.S. census and SEER, respectively. Risk-group 
classification was based on 14-gene RS clinical studies, and chemotherapy uptake 
was based on a study of pre/post testing recommendations from 58 surgeons/
oncologists. Included costs were those of the assay, chemotherapy with NCCN-
recommended regimens, monitoring, post-recurrence care, and adverse events. We 
calculated the total and per-member per-month (PMPM) 1-year budget impact of 
adding coverage for the 14-gene RS, and evaluated uncertainty using one-way sensi-
tivity analyses. Results: The 1-year budget impact of covering the 14-gene RS assay 
in commercial and Medicare health plans with 1 million members is expected to be 
$24,200 (PMPM= $0.002) and $178,800 (PMPM= $0.015), respectively. The most influen-
tial parameters were the proportion of high-risk patients receiving chemotherapy, 
the chemotherapy recurrence hazard ratio, and the proportion of patients receiving 
initial surgical treatment. ConClusions: Our analysis suggests that covering the 
14-gene RS assay is expected to increase chemotherapy use, decrease recurrences, 
and result in a small net increase in PMPM cost in commercial and Medicare health 
plans. These outcomes indicate that the assay has the potential to provide positive 
health outcomes for health plan members at a reasonable cost.
PCN38
estImatINg the Budget ImPaCt of CrIzotINIB for alk-PosItIve 
advaNCed NoN-small Cell luNg CaNCer (NsClC) IN argeNtINa
Wang B.1, Furnback W.1, Xuan J.2
1Alliance Life Sciences, Somerset, NJ, USA, 2Pfizer, Inc., New York, NY, USA
objeCtives: Non-small cell lung cancer (NSCLC) accounts for the majority of lung 
cancer cases and a high number of these patients have metastatic cancer at the time 
of diagnosis. The ALK mutation is only found in about 4% of NSCLC patients. The 
study aims to evaluate the budgetary impact of adding crizotinib for patients with 
